TITLE

Hepatitis B–lamivudine for all and forever?: Jung MO, Jinik K, Sung WC, Efficacy and Safety of Lamivudine in Korean Patients With Chronic Hepatitis B Virus With and Without Cirrhosis. Pharmacotherapy 2002;22:1226—34

AUTHOR(S)
Souney, Paul F.
PUB. DATE
August 2003
SOURCE
American Journal of Gastroenterology;Aug2003, Vol. 98 Issue 8, p1889
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
This retrospective study was designed to evaluate the safety and efficacy of long-term lamivudine therapy in Korean patients with chronic hepatitis B virus (HBV) with or without cirrhosis. Study patients were men and women who had received lamivudine 100 mg/day p.o. for 52 wk for treatment of biopsy-proven chronic HBV; 11/29 patients had cirrhosis. Patient eligibility requirements included having a diagnosis of chronic HBV, being positive for HBV by polymerase chain reaction, at least 18 yr of age, and positive for HBsAg, and having abnormally elevated ALT levels. Patients were evaluated for changes in HBV DNA and ALT concentrations, rates at which HBeAg was converted to negative, development of lamivudine resistance, and differences in the drug''s effectiveness between patients with and without cirrhosis. Responses of serum HBV DNA and ALT were categorized into three groups according to degree of response to lamivudine treatment: continuous, unstable, and no response.Twenty-nine patients were evaluated in this retrospective analysis. Therapy with lamivudine suppressed serum HBV DNA to undetectable levels in 97% of patients within 12 wk and remained undetectable in 83% of patients after 52 wk. Differences in responses of HBV DNA and ALT to lamivudine therapy in HBeAg-positive and -negative patients and in the development of drug resistance between patients with and without cirrhosis were negligible. Pretreatment HBV DNA and ALT levels had no effect on the efficacy of lamivudine (p = 0.9116).No serious adverse events were reported.
ACCESSION #
10428295

 

Related Articles

  • A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B. Spackman, D Eldon; Veenstra, David L // PharmacoEconomics;2008, Vol. 26 Issue 11, p937 

    BACKGROUND: A variety of pharmaceuticals are currently approved for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), but their relative economic value is unclear. The goal of this analysis was to compare the cost effectiveness of adefovir, entecavir, lamivudine,...

  • Antiviral Therapy for Hepatitis B in Pre- and Post-liver Transplant Patients. Mukherjee, Sandeep // Journal of Antivirals & Antiretrovirals;2009, Vol. 1 Issue 2, p17 

    Liver transplantation was approved for treatment of decompensated cirrhosis in the United States in 1983. Until the introduction of hepatitis B immunoglobulin and nucleoside/ nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal...

  • Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients. H. WANG; Y. Y. JI; G. B. YAO; X. Y. MA; Q. XIE; H. Y. PANG; S. M. WU; J. LI; C. W. CHEN; X. W. XU; E. L. GU // European Review for Medical & Pharmacological Sciences;Mar2013, Vol. 17 Issue 5, p636 

    BACKGROUND: Lamivudine (LAM) and adefovir (ADV) are widely used in most Asian countries, though monotherapy is associated with the occurrence of resistance. AIM: To evaluate the efficiency of LAM and ADV combined treatment of chronic hepatitis B patients with compensated cirrhosis. PATIENTS AND...

  • Chronic viral hepatitis: its characteristics and management. Brunetto, Maurizia R.; Balsano, Clara; Burra, Patrizia; Cariani, Elisabetta; Taliani, Gloria; Villa, Erica // Hot Topics in Viral Hepatitis;2011, Vol. 7 Issue 21, p11 

    Although most patients with liver disease remain asymptomatic throughout their life, chronic viral hepatitis is a major health problem because of the significant mortality rates of its complications--cirrhosis and hepatocellular carcinoma. Recent knowledge in the understanding of viral...

  • Suppressing Hepatitis B without Resistance – So Far, So Good. Mailliard, Mark E.; Gollan, John L. // New England Journal of Medicine;2/27/2003, Vol. 348 Issue 9, p848 

    The article presents the authors' comments on the management of hepatitis B. The authors mention that clinicians managing patients with chronic viral hepatitis face complex challenges. They say that the prime objective of therapy for chronic hepatitis is to heal hepatic inflammation and...

  • Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. Kurokawa, Mika; Hiramatsu, Naoki; Oze, Tsugiko; Yakushijin, Takayuki; Miyazaki, Masanori; Hosui, Atsushi; Miyagi, Takuya; Yoshida, Yuichi; Ishida, Hisashi; Tatsumi, Tomohide; Kiso, Shinichi; Kanto, Tatsuya; Kasahara, Akinori; Iio, Sadaharu; Doi, Yoshinori; Yamada, Akira; Oshita, Masahide; Kaneko, Akira; Mochizuki, Kiyoshi; Hagiwara, Hideki // Journal of Gastroenterology;May2012, Vol. 47 Issue 5, p577 

    Background: Nucleotide analogues have recently been approved for the treatment of patients with hepatitis B virus (HBV) infection. However, it is still controversial whether the decrease of HBV-DNA amount induced by treatment with nucleotide analogues can reduce the risk of hepatocellular...

  • The Treatment of Chronic Type B Viral Hepatitis. Aach, Richard D. // Annals of Internal Medicine;7/15/88, Vol. 109 Issue 2, p89 

    Editorial. Focuses on the treatment of chronic type B viral hepatitis in the U.S. as of July 1988. Estimate of acute hepatitis B cases according to the Centers for Disease Control; Factors that contribute to the probability of developing chronic infection; Therapeutic approaches and drugs...

  • Management of Hepatitis B Virus Infection in Liver Transplantation Setting The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran. Moayed Alavian, Seyed; Lankarani, Kamran B.; Rizzetto, Mario; Marzano, Alfredo; Moghadami, Mohsen; Nik-Eghbolian, Saman; Bahrani, Amin // Hepatitis Monthly;Dec2012, Vol. 12 Issue 12, p1 

    Hepatitis B infection is the main cause of liver related mortality in many countries including Iran. Liver transplantation in cirrhosis due to HBV infection before 1990 was an absolute contraindication. Recurrent infection was a significant event in post liver transplant setting and resulted in...

  • Tenofovir: New Hope for Hepatitis B Patients.  // Neurology Alert;May2013, Vol. 31 Issue 9, p10 

    The article discusses research by P. Marcellin and colleagues, published in a 2013 issue of "Lancet" on the use of tenofovir (TFV) in treating hepatitis B patients.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics